Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).
Cholelithiasis in patientes treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials / Nreu B.; Dicembrini I.; Tinti F.; Mannucci E.; Monami M.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - ELETTRONICO. - 161:(2020), pp. 108087-108087. [10.1016/j.diabres.2020.108087]
Cholelithiasis in patientes treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials
Nreu B.;Dicembrini I.;Mannucci E.;Monami M.
2020
Abstract
Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
